StockData

Immunome vs Xenetic Biosciences

IMNM and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMNM and XBIO compare

Immunome is the larger company, worth 517 times as much as Xenetic Biosciences ($2.0B against $3.8M).

Xenetic Biosciences grew revenue faster over the last twelve months (33.3% versus −63.3% for Immunome).

Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −75.9% compared with −5594% at Immunome.

Xenetic Biosciences scores higher on the StockData Score (12 against 7 for Immunome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMNMXBIO
Size and price
Market cap$2.0B$3.8M
Share price$17.18$1.61
Change, 1 year0.23%−38.1%
Change, 5 years1.2%−88.9%
Beta (5Y)1.621.14
Employees1772
StockData Score
Total score712 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score12 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S486×1.2× (better)
P/B3.3×0.6× (better)
FCF yield−10.5%–
Fair value–$4.53
Margin of safety–64.4%
Growth
Revenue growth (TTM)−63.3%33.3% (better)
Revenue growth, 5Y average–46.8%
Profitability
Operating margin−5948%−81.0% (better)
Net margin−5594%−75.9% (better)
FCF margin−5119%–
Return on equity−50.1%−47.0% (better)
Financial health
Debt / equity0.000.00
Current ratio21.68 (better)7.43
Altman Z-score35.70 (better)−37.70
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%6.5%
Held by insiders6.4%12.2%
Insider net buying, 12 months−$25.2M–
Short interest, % of float15.2%1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.